Yes. A current paid project seeks people with GLP-1 weight-loss side effects, with pay of $125 to $325 depending on the study. GLP-1 means weekly prescription drugs taken for weight loss, including brands like Wegovy.
One option is an Atlanta in-home interview, the other is a national daily diary. Both projects study real-world use, not a new drug test. Your fit depends on age, location, body mass index (BMI), and current use. BMI is a weight-for-height measure used for screening.
Table of Contents
- What does the $325 Atlanta interview involve?
- What does the $125 daily diary require?
- Why focus on nausea, vomiting, and diarrhea?
- What limits should you expect?
What does the $325 Atlanta interview involve?
PRC Global Market Research is recruiting adults ages 25-64 for Atlanta in-home interviews May 18-20, 2026. The interviews focus on GLP-1 weight loss. PRC Global Market Research lists the schedule and screener in the Atlanta study screener.
Selected participants complete a 2-hour interview plus a rescreen and homework. They must show proof of medication brand. Pay is $325 for full completion.
What does the $125 daily diary require?
Bridge Access Solutions runs a real-world diary study for current weekly GLP-1 users. Participants complete an 8-10 minute daily diary for 6 weeks. Bridge Access Solutions describes the daily task on the study enrollment page.
The diary asks about nausea, vomiting, diarrhea, and food and appetite relative to each dose. Pay is $125 upon completion. Eligibility centers on three checks:.
- U.S. adult age 18 or older who currently uses a GLP-1
- BMI of 30 or greater when treatment started
- Use for weight loss without diabetes
Why focus on nausea, vomiting, and diarrhea?
These are the most common GLP-1 reactions in federal labeling. Federal labeling for Wegovy lists nausea in 44%, diarrhea in 30%, and vomiting in 25% of treated adults. The National Library of Medicine DailyMed carries that labeling in the Wegovy labeling.
Rates often rise during dose escalation. That timing matters for a diary tied to each dose. Daily tracking can show when symptoms start, how long they last, and how appetite changes.
What limits should you expect?
The diary project is not a clinical trial. Bridge Access Solutions states it will not change or supply medication and will not cover GLP-1 costs. Keep taking your prescribed drug and follow your own doctor for care decisions.
Both opportunities are selective. PRC books first-come first-served and warns that not all screeners qualify or get callbacks. Bridge de-identifies feedback but may ask you to authorize medical-record access. Have your medication package, start date, and calendar ready before you apply.
